JAJet Wies Ankersmid

Jet Wies Ankersmid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jet Wies Ankersmid has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Shared decision-making supported by outcome information regarding surveillance after curative treatment for breast cancer: Results of the SHOUT-BC study

    by J.W. Ankersmid, C.H.C. Drossaert, L.J.A. Strobbe, M.Q.N. Hackert, N. Engels, J.C.M. Prick, S. Teerenstra, Y.E.A. van Riet, R. The, C.F. van Uden-Kraan, et al.


  • Open Access

    Evaluation of the Implementation of the Dutch Breast Cancer Surveillance Decision Aid including Personalized Risk Estimates in the SHOUT-BC Study: A Mixed Methods Approach

    by Jet W. Ankersmid, Ellen G. Engelhardt, Fleur K. Lansink Rotgerink, Regina The, Luc J. A. Strobbe, Constance H. C. Drossaert, Sabine Siesling, Cornelia F. van Uden-Kraan

    Background: To improve Shared decision-making (SDM) regarding personalized post-treatment surveillance, the Breast Cancer Surveillance Decision Aid (BCS-PtDA), integrating personalized risk information, was developed and implemented in eight hospitals. The aim of this mixed-methods study was to (1) assess the implementation and participation rates, (2) identify facilitators and barriers for use by health care professionals (HCPs), (3) quantify the observed level of SDM, and (4) evaluate risk communication and SDM application in consultations. Methods: Implementation and participation rates and patients’ BCS-PtDA use were calculated using hospital registry data and BCS-PtDA log data. HCPs’ perspective on facilitators and barriers were collected using the MIDI framework. Observed SDM levels in consultation transcripts were quantified using the OPTION-5 scale. Thematic analysis was performed to assess consultation content. Results: The average PtDA implementation and participation rates were, respectively, 26% and 61%. HCPs reported that the PtDA supported choice awareness. Reported barriers for implementation were mainly increased workload and a lack of perceived benefits. The consultation analysis (n = 64) showed patients were offered a choice, but deliberation was lacking. Risk communication was generally adequate. Discussion: When the BCS-PtDA was used, patients were clearly given a choice regarding their post-treatment surveillance, but information provision and SDM application can be improved.


  • Open Access

    Supporting Shared Decision-making About Surveillance After Breast Cancer With Personalized Recurrence Risk Calculations: Development of a Patient Decision Aid Using the International Patient Decision AIDS Standards Development Process in Combination With a Mixed Methods Design

    by Jet Wies Ankersmid, Sabine Siesling, Luc J A Strobbe, Johanna M Meulepas, Yvonne E A van Riet, Noel Engels, Janine C M Prick, Regina The, Asako Takahashi, Mirjam Velting, et al.

    Background: Although the treatment for breast cancer is highly personalized, posttreatment surveillance remains one-size-fits-all: annual imaging and physical examination for at least five years after treatment. The INFLUENCE nomogram is a prognostic model for estimating the 5-year risk for locoregional recurrences and second primary tumors after breast cancer. The use of personalized outcome data (such as risks for recurrences) can enrich the process of shared decision-making (SDM) for personalized surveillance after breast cancer. Objective: This study aimed to develop a patient decision aid (PtDA), integrating personalized risk calculations on risks for recurrences, to support SDM for personalized surveillance after curative treatment for invasive breast cancer. Methods: For the development of the PtDA, the International Patient Decision Aids Standards development process was combined with a mixed methods design inspired by the development process of previously developed PtDAs. In the development, 8 steps were distinguished: establishing a multidisciplinary steering group; definition of the end users, scope, and purpose of the PtDA; assessment of the decisional needs of end users; defining requirements for the PtDA; determining the format and implementation strategy for the PtDA; prototyping; alpha testing; and beta testing. The composed steering group convened during regular working-group sessions throughout the development process. Results: The “Breast Cancer Surveillance Decision Aid” consists of 3 components that support the SDM process: a handout sheet on which personalized risks for recurrences, calculated using the INFLUENCE-nomogram, can be visualized and which contains an explanation about the decision for surveillance and a login code for a web-based deliberation tool; a web-based deliberation tool, including a patient-reported outcome measure on fear of cancer recurrence; and a summary sheet summarizing patient preferences and considerations. The PtDA was assessed as usable and acceptable during alpha testing. Beta testing is currently ongoing. Conclusions: We developed an acceptable and usable PtDA that integrates personalized risk calculations for the risk for recurrences to support SDM for surveillance after breast cancer. The implementation and effects of the use of the “Breast Cancer Surveillance Decision Aid” are being investigated in a clinical trial.


  • Open Access

    Relations between recurrence risk perceptions and fear of cancer recurrence in breast cancer survivors

    by J. W. Ankersmid, F. K. Lansink Rotgerink, L. J. A. Strobbe, C.F. van Uden-Kraan, S. Siesling, C. H. C. Drossaert

    Purpose: This study aimed to: (1) determine the accuracy of Dutch breast cancer survivors’ estimations of the locoregional recurrence risk (LRR); (2) examine which variables influence (the accuracy of) risk estimations, and risk appraisals; and (3) investigate the influence of the objective LRR risk (estimated using the INFLUENCE-nomogram), risk estimations and risk appraisals on fear of cancer recurrence (FCR). Findings of this study will inform clinicians on risk communication and can improve communication about FCR. Methods: In a cross-sectional survey among 258 breast cancer survivors, women’s recurrence risk estimations (in odds) and risk appraisals (in high/low), FCR, demographics and illness perceptions, about one year after surgery were measured and compared to the objective risk for LRRs estimated using the INFLUENCE-nomogram. Results: Half of the women (54%) accurately estimated their LRR risk, 34% underestimated and 13% overestimated their risk. Risk estimations and risk appraisals were only moderately positively correlated (r = 0.58). Higher risk appraisals were associated with radiotherapy (r = 0.18) and having weaker cure beliefs (r = − 0.19). Younger age was associated with overestimation of risk (r = − 0.23). Recurrence risk estimations and risk appraisals were associated with more FCR (r = 0.29, r = 0.39). In regression, only risk appraisal contributed significantly to FCR. Conclusion: Although women were fairly accurate in recurrence risk estimations, it remains difficult to predict over- or underestimation. Recurrence risk estimations and risk appraisal are two different concepts which are both associated with FCR and should therefore be addressed in patient-provider communication.


  • Open Access

    Health care professionals' perspectives on shared decision making supported by personalised‐risk‐for‐recurrences‐calculations regarding surveillance after breast cancer

    by Jet W. Ankersmid, Constance H. C. Drossaert, Luc J. A. Strobbe, Melissa S. Battjes, Cornelia F. van Uden‐Kraan, Sabine Siesling, the Santeon VBHC Breast Cancer Group, Yvonne E. A. van Riet, José M. Bode‐Meulepas, Anneriet E. Dassen, et al.

    Objective Breast cancer patients for whom less intensive surveillance is sufficient can be identified based on the risk for locoregional recurrences (LRRs). This study explores health care professionals' (HCPs) perspectives on less intensive surveillance, preferences for shared decision-making (SDM) about surveillance and perspectives on the use of patients' estimated personal risk for LRRs in decision-making about surveillance. Methods We conducted semi-structured interviews with 21 HCPs providing follow-up care for breast cancer patients in seven Dutch teaching hospitals (Santeon hospitals). Results HCPs were predominantly positive about less intensive surveillance for women with a low risk for recurrences. They mentioned important prerequisites such as clearly defined surveillance schedules based on risk categories, information provision and communication support for patients and HCPs. Most HCPs supported SDM about surveillance and were positive about using patients' estimated personal risk for LRRs. HCPs specified prerequisites such as clear visualisation and explanation of risk information, attention for fear of cancer recurrence (FCR) and defined surveillance schedules for specific risk groups. Conclusion Mentioned prerequisites for less intensive surveillance need to be accounted for. Information needs and existing misconceptions need to be addressed. Outcome information regarding risks for LRRs and FCR can enrich the SDM process about surveillance.


  • Open Access

    Supporting shared decision making about personalised surveillance after breast cancer: the development of a patient decision aid integrating personalised recurrence risk calculations (Preprint)

    by Jet Wies Ankersmid, Sabine Siesling, Luc J A Strobbe, José M Bode-Meulepas, Yvonne E A van Riet, Noel Engels, Janine C M Prick, Regina The, Asako Takahashi, Mirjam Velting, et al.

    UNSTRUCTURED Background and objective: The aim of this study was to develop a patient decision aid (PtDA), integrating personalised risk calculations on risks for recurrences, to support shared decision-making (SDM) about personalised surveillance after curative treatment for invasive breast cancer. Methods: For the development of the PtDA, the International Patient Decision Aids Standards (IPDAS) development process was combined with a mixed-methods design consisting of decisional needs assessment studies, prototyping, and alpha and beta testing. The composed steering group convened in regular working group sessions throughout the development process. Results: The “Breast Cancer Surveillance Decision Aid” consists of three components that each support a step in the SDM process: 1) a handout sheet on which personalised risks for recurrences, calculated using the INFLUENCE-nomogram, can be visualised and which contains explanation about the decision for post-treatment surveillance and a login code for an online deliberation tool; 2) an online deliberation tool, including a patient reported outcome measure on fear of cancer recurrence; and 3) a summary sheet summarising patients’ preferences and considerations. The PtDA was assessed as usable and acceptable during alpha testing. Conclusions: We developed an acceptable and usable PtDA integrating personalised risk calculations on risks for recurrences to support SDM about surveillance after breast cancer. The implementation and effects of the use of the “Breast Cancer Surveillance Decision Aid” are currently being investigated in a clinical trial.

  • Open Access

    Health care professionals overestimate the risk for locoregional recurrences after breast cancer treatment depending on their specialty

    by Jet W. Ankersmid, Pauline E. R. Spronk, Anneke M. Zeillemaker, Sabine Siesling

    Purpose: For the implementation of personalised surveillance, it is important to create more awareness among HCPs with regard to the risk for locoregional recurrences (LRRs). The aim of this study is to evaluate the current awareness and estimations of individual risks for LRRs after completion of primary treatment for breast cancer among health care professionals (HCPs) in the Netherlands, without using any prediction tools. Methods: A cross-sectional survey was performed among 60 HCPs working in breast cancer care in seven Dutch hospitals and 25 general practitioners (GPs). The survey consisted of eleven realistic surgically treated breast cancer cases. HCPs were asked to estimate the 5-year risk for LRRs for each case, which was compared to the estimations by the INFLUENCE-nomogram using one-sample Wilcoxon tests. Differences in estimations between HCPs with different specialities were determined using Kruskal–Wallis tests and Dunn tests. Results: HCPs tended to structurally overestimate the 5-year risk for LRR on each case. Average overestimations ranged from 4.8 to 26.1%. Groups of HCPs with varying specialities differed significantly in risk estimations. GPs tended to overestimate the risk for LRRs on average the most (15.0%) and medical oncologists had the lowest average overestimation (2.7%). Conclusions: It is important to create more awareness of the risk for LRRs, which is a pre-requisite for the implementation of personalised surveillance after breast cancer. Besides education for HCPs, the use of prediction models such as the INFLUENCE-nomogram can support in estimating an objective estimate of each individual patient’s risk.


  • Open Access

    Abstract P5-15-02: The risk for locoregional breast cancer recurrences: Significant differences in perceptions among health care professionals (HCPs)

    by Jet W. Ankersmid, Pauline E.R. Spronk, Anneke M. Zeillemaker, Sabine Siesling

    Introduction: Unlike the highly personalized breast cancer treatment, surveillance in the Netherlands is still ‘one-size-fits-all’: annual imaging and physical examination for at least five year after treatment. To identify patients with a low or high risk for locoregional recurrences (LRRs) who might benefit from less or more intensive surveillance, risk prediction models can be used. The INFLUENCE-nomogram is an example of this and is developed using on data of the Netherlands Cancer Registry. It remains unclear to which extent health care professionals (HCPs) are able to accurately estimate the patient individual risk for locoregional recurrences. Objective: To evaluate the current awareness, knowledge and ability to estimate patients individual risks for locoregional recurrences after breast cancer - without using any prediction tools - among HCPs in the Netherlands. Methods: In this study, a cross-sectional survey was performed among general practitioners (GPs) and HCPs working in breast cancer care in six teaching hospitals in the Netherlands. In total, 85 HCPs (25 GPs and 60 hospital HCPs) participated. HCPs received descriptions of eleven breast cancer cases with different patient-, tumor- and treatment characteristics for which they were asked to estimate the risk for LRRs. The estimations were compared among different groups of HCPs and with the estimation calculated using the INFLUENCE-nomogram. Results: HCPs structurally overestimated the risk for LRRs (ranging from an average overestimation from 4% on one case to 26% on another case). In nine out of eleven cases, significant differences in risk estimates were found between groups of HCPs. In five of the eleven cases, GPs had a significantly higher median estimate than medical oncologists (respectively 10 % vs. 2.5 %; 15 % vs. 5 %; 25 % vs. 6.5 %; 25% vs. 6.5 %; 8 % vs. 1 %; and 12 % vs. 2% on these five cases). Conclusion: The structural overestimation of the risks stresses the importance to create more awareness and knowledge of the risk for LRRs after breast cancer. Medical oncologists seem to estimates risks for recurrences more accurately then GPs. This might be due to the fact that medical oncologists have more experience with the use of risk prediction models (such as Predict) in clinical practice. More awareness and knowledge of the risk for LRRs can be generated using objective estimations by prediction models. This will support the implementation of personalized surveillance after breast cancer. Citation Format: Jet W. Ankersmid, Pauline E.R. Spronk, Anneke M. Zeillemaker, Sabine Siesling. The risk for locoregional breast cancer recurrences: Significant differences in perceptions among health care professionals (HCPs) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-15-02.

  • Open Access

    Needs and preferences of breast cancer survivors regarding outcome-based shared decision-making about personalised post-treatment surveillance

    by Jet W. Ankersmid, Constance H. C. Drossaert, Yvonne E. A. van Riet, Luc J. A. Strobbe, Sabine Siesling, on behalf of the Santeon VBHC Breast Cancer Group

    Purpose: In this study, we explored how patients experience current information provision and decision-making about post-treatment surveillance after breast cancer. Furthermore, we assessed patients’ perspectives regarding less intensive surveillance in case of a low risk of recurrence. Methods: We conducted semi-structured interviews with 22 women in the post-treatment surveillance trajectory in seven Dutch teaching hospitals. Results: Although the majority of participants indicated a desire for shared decision-making (SDM) about post-treatment surveillance, participants experienced no SDM. Information provision was often suboptimal and unstructured. Participants were open for using risk information in decision-making, but hesitant towards less intensive surveillance. Perceived advantages of less intensive surveillance were: less distressing moments, leaving the patient role behind, and lower burden. Disadvantages were: fewer moments for reassurance, fear of missing recurrences, and a higher threshold for aftercare for side effects. Conclusions: SDM about post-treatment surveillance is desirable. Although women are hesitant about less intensive surveillance, they are open to the use of personalised risk assessment for recurrences in decision-making about surveillance. Implications for Cancer Survivors: To facilitate SDM about post-treatment surveillance, the timing and content of information provision should be improved. Risk information should be provided in an accessible and understandable way. Moreover, fear of cancer recurrence and other personal considerations should be addressed in the process of SDM.


  • Open Access

    Follow‐up after breast cancer: Variations, best practices, and opportunities for improvement according to health care professionals

    by Jet W. Ankersmid, Jolanda C. Hoeve, Luc J. A. Strobbe, Yvonne E. A. Riet, Cornelia F. Uden‐Kraan, Sabine Siesling, Constance H. C. Drossaert, the Santeon VBHC Breast Cancer Group

    Objective Follow-up after breast cancer can be divided into surveillance and aftercare. It remains unclear how follow-up can ideally be organised from the perspective of health care professionals (HCPs). The aim of this study was to gain insight in the organisation of follow-up in seven Dutch teaching hospitals and to identify best practices and opportunities for improvement of breast cancer (all stages) follow-up as proposed by HCPs. Methods Semi-structured in-depth group interviews were performed, one in each of the participating hospitals, with in total 16 HCPs and 2 patient advocates. To describe the organisation of follow-up, transcripts were analysed using a deductive approach. Best practices and opportunities were derived using an inductive approach. Results Variation was found in the organisation of aftercare, especially in timing, frequency, and disciplines of involved HCPs. Less variation was observed for surveillance, which was guided by the national guideline. Best practices focused on case management and adequate collaboration between HCPs of different disciplines. Mentioned opportunities were improving the structured monitoring of patients' needs and a comprehensive guideline for organisation and content of aftercare. Conclusions Variation in follow-up existed between hospitals. Shared decision-making (SDM) about surveillance is desirable to ensure that surveillance matches the patient needs, preferences, and personal risk for recurrences.